Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906562 · ClinicalTrials.gov registry record · Phase 2
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
A Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, sponsored by Sameek Roychowdhury.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT06906562 is a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by Sameek Roychowdhury. The registered enrollment target is 40 participants, below the 87-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06906562, a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by Sameek Roychowdhury.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body (metastatic) and that have abnormal changes (alterations) in the fibroblast growth factor receptor (FGFR) gene. FGFR genes are genes that, when altered, can lead to and promote the growth of cancer in patients. Researchers want to test if using pemigatinib can block the function of these abnormal FGFR genes and prevent the tumor from growing and whether treatment can help improve overall quality of life.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Bone Scan
- PROCEDURE Computed Tomography (CT)
- DRUG Pemigatinib
- PROCEDURE Optical Coherence Tomography
Study Locations (20)
California
- Ohio State University Telemedicine - Fresno
- Ohio State University-Telemedicine - Los Angeles
- Ohio State University-Telemedicine - San Diego
- Ohio State University-Telemedicine - San Francisco
Colorado
- Ohio State University-Telemedicine - Aurora
- Ohio State University Telemedicine - Denver
- Ohio State University Telemedicine - Durango
- Ohio State University Telemedicine - Grand Junction
Alabama
- Ohio State University-Telemedicine - Birmingham
- Ohio State University-Telemedicine - Mobile
- Ohio State University Telemedicine - Montgomery
Arizona
- Ohio State University Telemedicine - Flagstaff
- Ohio State University-Telemedicine - Phoenix
- Ohio State University-Telemedicine - Tucson
Alaska
- Ohio State University-Telemedicine - Anchorage
Arkansas
- Ohio State University-Telemedicine - Hot Springs
Connecticut
- Ohio State University-Telemedicine - New Haven
Delaware
- Ohio State University-Telemedicine - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906562
The ClinicalTrials.gov registry entry for NCT06906562 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (54% lower). The listed sponsor is Sameek Roychowdhury, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IV Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT06906562 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06906562 about?
NCT06906562 is a clinical study titled "A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations". This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body...
What is the current status of trial NCT06906562?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-26. Estimated completion is 2028-12-31.
What conditions does trial NCT06906562 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Metastatic Pancreatic Carcinoma, Advanced Pancreatic Carcinoma.
What interventions are being tested in trial NCT06906562?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE), Computed Tomography (CT) (PROCEDURE), Pemigatinib (DRUG), Optical Coherence Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT06906562?
This trial is sponsored by Sameek Roychowdhury, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906562 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
RECRUITING · Phase 2
-
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Pancreatic Cancer AJCC v8
All registered trials for this condition
Stage III Pancreatic Cancer AJCC v8
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.